VE-821, Inhibitor

VE-821

Cat. Num. AAA386356

• Purity: >98%
• Synonyms: VE-821; VE821; inhibitor

• Purity/Purification: >98%
• Form/Format: Powder
• Concentration: 0.1 mM: 21.35 mL (1 mg); 106.75 mL (5 mg); 213.49mL (10 mg); 0.5 mM: 4.27 mL (1 mg); 21.35 mL (5 mg); 42.7 mL (10 mg); 1 mM: 2.13 mL (1 mg); 10.67 mL (5 mg); 21.35 mL (10 mg); 5 mM: 0.43 mL (1 mg); 2.13 mL (5 mg); 4.27 mL (10 mg) (varies by lot)

• CAS Number: 1232410-49-9
• Formula: C18H16N4O3S
• SMILES: CS(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C(=O)NC3=CC=CC=C3)N
• Actions: Inhibitor
• In Vivo Solvent: 30% PEG400/0.5% Tween80/5% propylene glycol
• Solubility (DMSO): 74 mg/mL (200.86 mM)
• Solubility (Ethanol): <1 mg/mL (<1 mM)
• Solubility (in vivo): 30 mg/mL
• Solubility (Water): <1 mg/mL (<1 mM)
• Availability: We cannot ship this item to Switzerland, Italy, Germany, France and Austria.
• Preparation and Storage: at -20 degree C 3 years Powder

Chemical Structure

Related Product Information for VE-821, inhibitor

VE-821 is a potent and selective inhibitor of protein kinase ATR.

References

Mitsuru Sasaki-Honda, .et al. A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4, Hum Mol Genet, 2018, Dec 1; 27(23): 4024-4035 PMID: 30107443
Kim J, .et al. Replication Stress Shapes a Protective Chromatin Environment across Fragile Genomic Regions, Mol Cell, 2018, Jan 4;69(1):36-47.e7 PMID: 29249653
Antonio Postigo, .et al. Cytoplasmic ATR Activation Promotes Vaccinia Virus Genome Replication, Cell Rep, 2017, May 2; 19(5): 1022-1032 PMID: 28467896
Nnennaya Kanu, .et al. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer, Genome Biol, 2016, 17: 185 PMID: 27634334
Carolyn Botting, .et al. H2AX phosphorylation and DNA damage kinase activity are dispensable for herpes simplex virus replication, Virol J, 2016, 13: 15 PMID: 26817608